Sarcoma  >>  Neulasta (pegfilgrastim) 
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neulasta (pegfilgrastim) / Roche
NCT01933932 / 2013-001676-38: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Checkmark SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Aug 2016 - Aug 2016: SELECT-1 (selumetinib + docetaxel combo) trial for KRAS-mutant NSCLC
Checkmark Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Jan 2016 - Jan 2016: Enrollment completion in P3 SELECT-1 trial in 2L KRASm NSCLC
Checkmark Pivotal trial initiation in 2nd-line KRASm NSCLC
More
Active, not recruiting
3
510
Europe, Canada, US, RoW
Selumetinib, AZD6244; ARRY-142886, Docetaxel, Placebo, Pegylated G-CSF, Pegfilgrastim 6 mg
AstraZeneca
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
06/16
12/24
NCT05043649: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

Terminated
1
14
US
Camsirubicin
Monopar Therapeutics
Advanced Soft-tissue Sarcoma
10/23
05/24

Download Options